Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma

Yundeok Kim, Soo Jeong Kim, June Won Cheong, Hyunsoo Cho, Haerim Chung, Jung Yeon Lee, Ji Eun Jang, Yoo Hong Min, Jin Seok Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We conducted a retrospective study to evaluate the clinical impact of an early recovery of posttransplant absolute lymphocyte count (ALC) on the outcome of frontline autologous stem cell transplantation (ASCT) for diffuse large B-cell lymphoma (DLBCL). We reviewed 65 DLBCL patients who underwent frontline ASCT after primary chemotherapy based on cyclophosphamide, doxorubicin, vincristine, and prednisone. A receiver operating characteristic analysis was performed to determine the optimal cut point (0.4 × 109/L) for an ALC at 15 days after ASCT (ALC-15). Both event-free survival and overall survival rates of the higher-ALC-15 group were significantly better than those of the lower-ALC-15 group (event-free survival, P =.008; overall survival, P =.013). The infused CD34+ cell count was significantly associated with the recovery of ALC-15 (>0.4 × 109/L) after ASCT (P =.028). A multivariate analysis confirmed that a higher infused CD34+ cell dose (>5.0 × 106 cells/kg) was an independent factor affecting an early recovery of ALC after ASCT (odds ratio, 4.145; 95% confidence interval, 1.106-15.528; P =.035). In conclusion, an early recovery of ALC after ASCT can be regarded as a good prognostic marker in patients with DLBCL who have undergone frontline ASCT. We found that the infused CD34+ cell dose for ASCT was associated with the recovery of ALC.

Original languageEnglish
Pages (from-to)465-471
Number of pages7
JournalHematological Oncology
Volume35
Issue number4
DOIs
Publication statusPublished - 2017 Dec

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Lymphocyte Count
Stem Cell Transplantation
Disease-Free Survival
Vincristine
Prednisone
ROC Curve
Doxorubicin
Cyclophosphamide
Multivariate Analysis
Survival Rate
Retrospective Studies
Cell Count
Odds Ratio
Confidence Intervals
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Kim, Yundeok ; Kim, Soo Jeong ; Cheong, June Won ; Cho, Hyunsoo ; Chung, Haerim ; Lee, Jung Yeon ; Jang, Ji Eun ; Min, Yoo Hong ; Kim, Jin Seok. / Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma. In: Hematological Oncology. 2017 ; Vol. 35, No. 4. pp. 465-471.
@article{5cdc8f1c59c64712aa254e92f45c119c,
title = "Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma",
abstract = "We conducted a retrospective study to evaluate the clinical impact of an early recovery of posttransplant absolute lymphocyte count (ALC) on the outcome of frontline autologous stem cell transplantation (ASCT) for diffuse large B-cell lymphoma (DLBCL). We reviewed 65 DLBCL patients who underwent frontline ASCT after primary chemotherapy based on cyclophosphamide, doxorubicin, vincristine, and prednisone. A receiver operating characteristic analysis was performed to determine the optimal cut point (0.4 × 109/L) for an ALC at 15 days after ASCT (ALC-15). Both event-free survival and overall survival rates of the higher-ALC-15 group were significantly better than those of the lower-ALC-15 group (event-free survival, P =.008; overall survival, P =.013). The infused CD34+ cell count was significantly associated with the recovery of ALC-15 (>0.4 × 109/L) after ASCT (P =.028). A multivariate analysis confirmed that a higher infused CD34+ cell dose (>5.0 × 106 cells/kg) was an independent factor affecting an early recovery of ALC after ASCT (odds ratio, 4.145; 95{\%} confidence interval, 1.106-15.528; P =.035). In conclusion, an early recovery of ALC after ASCT can be regarded as a good prognostic marker in patients with DLBCL who have undergone frontline ASCT. We found that the infused CD34+ cell dose for ASCT was associated with the recovery of ALC.",
author = "Yundeok Kim and Kim, {Soo Jeong} and Cheong, {June Won} and Hyunsoo Cho and Haerim Chung and Lee, {Jung Yeon} and Jang, {Ji Eun} and Min, {Yoo Hong} and Kim, {Jin Seok}",
year = "2017",
month = "12",
doi = "10.1002/hon.2332",
language = "English",
volume = "35",
pages = "465--471",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma. / Kim, Yundeok; Kim, Soo Jeong; Cheong, June Won; Cho, Hyunsoo; Chung, Haerim; Lee, Jung Yeon; Jang, Ji Eun; Min, Yoo Hong; Kim, Jin Seok.

In: Hematological Oncology, Vol. 35, No. 4, 12.2017, p. 465-471.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma

AU - Kim, Yundeok

AU - Kim, Soo Jeong

AU - Cheong, June Won

AU - Cho, Hyunsoo

AU - Chung, Haerim

AU - Lee, Jung Yeon

AU - Jang, Ji Eun

AU - Min, Yoo Hong

AU - Kim, Jin Seok

PY - 2017/12

Y1 - 2017/12

N2 - We conducted a retrospective study to evaluate the clinical impact of an early recovery of posttransplant absolute lymphocyte count (ALC) on the outcome of frontline autologous stem cell transplantation (ASCT) for diffuse large B-cell lymphoma (DLBCL). We reviewed 65 DLBCL patients who underwent frontline ASCT after primary chemotherapy based on cyclophosphamide, doxorubicin, vincristine, and prednisone. A receiver operating characteristic analysis was performed to determine the optimal cut point (0.4 × 109/L) for an ALC at 15 days after ASCT (ALC-15). Both event-free survival and overall survival rates of the higher-ALC-15 group were significantly better than those of the lower-ALC-15 group (event-free survival, P =.008; overall survival, P =.013). The infused CD34+ cell count was significantly associated with the recovery of ALC-15 (>0.4 × 109/L) after ASCT (P =.028). A multivariate analysis confirmed that a higher infused CD34+ cell dose (>5.0 × 106 cells/kg) was an independent factor affecting an early recovery of ALC after ASCT (odds ratio, 4.145; 95% confidence interval, 1.106-15.528; P =.035). In conclusion, an early recovery of ALC after ASCT can be regarded as a good prognostic marker in patients with DLBCL who have undergone frontline ASCT. We found that the infused CD34+ cell dose for ASCT was associated with the recovery of ALC.

AB - We conducted a retrospective study to evaluate the clinical impact of an early recovery of posttransplant absolute lymphocyte count (ALC) on the outcome of frontline autologous stem cell transplantation (ASCT) for diffuse large B-cell lymphoma (DLBCL). We reviewed 65 DLBCL patients who underwent frontline ASCT after primary chemotherapy based on cyclophosphamide, doxorubicin, vincristine, and prednisone. A receiver operating characteristic analysis was performed to determine the optimal cut point (0.4 × 109/L) for an ALC at 15 days after ASCT (ALC-15). Both event-free survival and overall survival rates of the higher-ALC-15 group were significantly better than those of the lower-ALC-15 group (event-free survival, P =.008; overall survival, P =.013). The infused CD34+ cell count was significantly associated with the recovery of ALC-15 (>0.4 × 109/L) after ASCT (P =.028). A multivariate analysis confirmed that a higher infused CD34+ cell dose (>5.0 × 106 cells/kg) was an independent factor affecting an early recovery of ALC after ASCT (odds ratio, 4.145; 95% confidence interval, 1.106-15.528; P =.035). In conclusion, an early recovery of ALC after ASCT can be regarded as a good prognostic marker in patients with DLBCL who have undergone frontline ASCT. We found that the infused CD34+ cell dose for ASCT was associated with the recovery of ALC.

UR - http://www.scopus.com/inward/record.url?scp=85038444765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038444765&partnerID=8YFLogxK

U2 - 10.1002/hon.2332

DO - 10.1002/hon.2332

M3 - Article

C2 - 27440113

AN - SCOPUS:85038444765

VL - 35

SP - 465

EP - 471

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 4

ER -